Haisco Pharmaceutical Group stock

002653 · SZSE · CNY

Compare Haisco Pharmaceutical Group
¥52.48Change from previous close: −2.13%Absolute change: −¥1.14

Close · November 20, 2026

Price history

−7.41% over the period

1 year: from ¥56.68 (November 20, 2025) to ¥52.48 (November 20, 2026), −7.41%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026¥52.48
October 30, 2026¥54.82
September 30, 2026¥62.18
August 31, 2026¥66.81
July 31, 2026¥62.38
June 30, 2026¥66.34
May 29, 2026¥51.57
April 30, 2026¥58.53
March 31, 2026¥54.28
February 27, 2026¥46.65
January 30, 2026¥50.68
December 31, 2025¥51.32
November 28, 2025¥59.82
November 20, 2025¥56.68

At a glance

  • The company

    Researches, develops, manufactures and sells pharmaceutical products for anesthesia, endocrine, cardiovascular, psychiatric, oncology and other therapeutic areas in China

  • Latest results

    Quarter to September 30, 2026 · EPS ¥0.46 (estimate ¥0.38)

TickerLandia's take on Haisco Pharmaceutical Group

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low¥42.38
52-wk high¥80.83

−35.07% from the 52-week high

Analysts · 4 analysts

Average target¥88.47+68.57% vs. price

Buy 4 · Hold 0 · Sell 0

TickerLandia Fingerprint: Haisco Pharmaceutical Group

Compared with similar companies: very high earnings stability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Haisco Pharmaceutical Group is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Haisco Pharmaceutical Group's P/E today is 228.2, above the median of its last 10 fiscal years (57.7; between 29.7 and 223.1 from 2016 to 2025). Haisco Pharmaceutical Group's P/E (trailing 12 months): 44.1, +6% against the median of a group of 8 similar companies (41.7).

P/E compared with its history

Compared with 8 similar companies

Haisco Pharmaceutical Group's metrics compared with similar companies
MetricHaisco Pharmaceutical GroupPosition in the groupBand
P/E (trailing 12 months)44.1Middle
Forward P/E38.0Middle
Operating margin21.1%Middle
ROE25.6%High
Debt/equity0.38Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Haisco Pharmaceutical Group. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥1.87B

Latest quarter · Q3 2026

Net income

¥525.25M

Latest quarter · Q3 2026

Quarterly net margin

28.0%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
¥59.87B
P/E
44.1
EPS
¥1.19
Volume
3.74M
Daily trading
€32.45M
Dividend yield
1.51%
Last ex-dividend on September 4, 2026

How Haisco Pharmaceutical Group is changing

All results
  • Revenue grew 5.7% a year on average over the last 5 years

  • Less cash than profit: free cash flow equal to 54% of net income

  • Shares outstanding up 4.6% in 5 years

Returns

Haisco Pharmaceutical Group returns with dividends

¥1,000 invested in Haisco Pharmaceutical Group 5 years ago, on November 22, 2021, would be worth ¥2,820 today with dividends reinvested: +182.04% in total, +23.08% per year. On price alone it would be ¥2,704 (+170.38%).

PeriodHaisco Pharmaceutical Group¥1,000 becomes
1 month−11.95%¥881
6 months+0.54%¥1,005
Year to date+2.26%¥1,023
1 year−6.23%¥938
3 years+127.72%¥2,277
5 years+182.04%¥2,820
10 years+235.18%¥3,352

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Haisco Pharmaceutical Group: technical analysis

Haisco Pharmaceutical Group shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 33.7% below its all-time closing high (¥79.19, July 16, 2026).

Trend
No clear trend
RSI (14 sessions)
33
Between 30 and 70
vs 200-session average
−9.18%

Active signals

  • Close below the low of the previous 55 sessions.

  • The last session opened more than 3% above the previous close.

Support and resistance

Price areas where Haisco Pharmaceutical Group has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance¥61.96+18.05%8 touches, last on November 5, 2026
  2. Resistance¥58.66+11.78%3 touches, last on August 3, 2026
  3. Resistance¥54.66+4.16%5 touches, last on November 2, 2026
  4. Last price¥52.48
  5. Support¥52.35−0.25%3 touches, last on April 9, 2026
  6. Support¥50.53−3.73%4 touches, last on June 12, 2026
  7. Support¥45.99−12.37%2 touches, last on June 9, 2026

Volatility and risk

Volatility (60 sessions, annualised)
41.1%
Largest fall in the last year
−33.73%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Haisco Pharmaceutical Group: seasonality

Average monthly price change over 15 years

+0.7%Jan+3.1%Feb+7.7%Mar+1.4%Apr+5.4%May+3.4%Jun+2.0%Jul+3.0%Aug−0.3%Sep+1.4%Oct−2.5%Nov−3.1%Dec

Over the last 15 years, the strongest month for Haisco Pharmaceutical Group has been March: +7.70% on average, positive in 9 years out of 15. The weakest has been December: −3.09% on average, positive in 4 years out of 14. November, the current month, has been positive in 6 years out of 14 (−2.54% on average).

Show chart data
MonthAverageMedianPositive years
January+0.66%−1.28%6 of 14
February+3.05%+2.61%9 of 15
March+7.70%+13.23%9 of 15
April+1.42%+0.80%9 of 15
May+5.42%+3.94%10 of 15
June+3.44%−0.50%7 of 15
July+1.99%−2.03%7 of 15
August+3.00%+6.18%10 of 15
September−0.27%+0.97%8 of 15
October+1.37%+3.08%9 of 15
November−2.54%−1.77%6 of 14
December−3.09%−4.37%4 of 14

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Haisco Pharmaceutical Group and its competitors

China is the main market for Haisco Pharmaceutical Group Co., Ltd., which researches, develops, manufactures and sells pharmaceutical products there. Its portfolio covers anesthesia and analgesic drugs, endocrine system treatments, enteral and parenteral nutrition products, cardiovascular, psychiatric, tumor-related and digestive liver disease medicines, and treatments for other diseases. The group also works with Eli Lilly on medicines spanning several therapeutic fields, and it changed its name from Xizang Haisco Pharmaceutical Group in March 2016.

Headquarters
Shannan, China
Employees
5,597
Founded
2000
Chief executive
Pangke Yan
Haisco Pharmaceutical Group and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Haisco Pharmaceutical Group002653$8.97B21.1%44.1+0.54%
ALTEOGEN196170$9.05B47.2%97.1−36.93%
Genscript Biotech1548$8.77B14.9%—+112.07%
Pharmaron Beijing300759$10.59B14.0%39.3+44.36%
Sino Biopharmaceutical1177$11.65B28.2%34.2−1.26%
Akeso9926$6.81B-30.7%—−50.70%

Same industry or related industries, similar size. Compare Haisco Pharmaceutical Group with its competitors · Full profile